ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE

Transcription

1 ANIL K. CHAGARLAMUDI, M.D. CURRICULUM VITAE PERSONAL DATA: DATE OF BIRTH: April 23, 1959 PLACE OF BIRTH: Amalapuam, A.P., India EDUCATION: COLLEGE: Andhra Christian College BS Degree Andhra Loyola College Vijayawada, A.P., India Pre-Med MEDICAL SCHOOL: Guntur Medical College Medical Doctor September 1979 October 1984 Graduated 1987 Externship Government General Hospital January 1985 September 1985 Externship Medicine and Surgery Fairview General Hospital Lorain, OH January 1986 October 1986 POSTGRADUATE TRAINING: General Surgery Residency: SUNY at Stony Brook Stony Brook, NY July 1990 June 1993 Internal Medicine Residency: July 1997 June 2000 Cardiology Fellowship: Westchester Medical Center, NYMC Valhalla, NY July 2000 June 2003

2 PRESENT POSITION: Staff Cardiologist Director of Endovascular Venous Therapy Director of Venous Imaging Cardiovascular Institute of the South/Houma 225 Dunn Street Houma, Louisiana August 1, 2003 to present LICENSURE: Louisiana 15183R New York Inactive Delaware C Inactive EXPERIENCE: House Fellow Cardiac Surgery October 1988 June 1990 House Fellow Cardiac Surgery July 1993 June 1997 PROFESSIONAL SOCIETIES: Louisiana State Medical Society ACADEMIC APPOINTMENT: Clinical Instructor in Surgery SUNY at Stony Brook Stony Brook, NY July 1990 June 1993 CERTIFICATION: American Board of Internal Medicine Internal Medicine HOSPITAL PRIVILEGES: Terrebonne General Medical Center Houma, Louisiana Thibodaux Regional Medical Center Thibodaux, LA Ochsner St. Anne General Hospital Raceland, LA AMG Specialty Hospital - Houma Houma, LA

3 HOSPITAL PRIVILEGES: (continued) Lady of the Sea Hospital Cutt Off, LA Lane Regional Medical Center Zachary, LA Teche Regional Medical Center Morgan City, LA AWARDS: Certificate of Excellence 1995 Medical Center of Delaware PHARMACEUTICAL TRIALS Sub- Investigator: September 29, Ongoing Regado Biosciences IND No. 63,275 A randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing The Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome (RADAR) Protocol ID: REG1-CLIN211 Terrebonne General Medical Center, Houma, LA Sub-Investigator: May 19, 2008 Ongoing Novartis Pharmaceuticals Corp. A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo controlled, parallelgroup study to evaluate the efficacy and safety of study medication on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy. (The ASPIRE Extension) Cardiovascular Institute of the South, Houma, LA

4 Sub-Investigator: 2008 Ongoing Sanofi Avenitis Randomized, multinational, double-blind study, comparing a high dose regimen of clopidogrel versus standard dose in patients with unstable angina or non-st segment elevation myocardial infarction managed with an early invasive strategy (The CURRENT/OASIS 7 Trial) Terrebonne General Medical center, Houma, LA Sub-Investigator: October 2008 Ongoing CALGENIX A randomized, double-blind, placebo controlled study to evaluate the use of study drug nutraceutical product vs. placebo in treatment of patients with elevated coronary calcium scores. (The CALGENIX) Trial) Cardiovascular Institute of the South, Houma, LA Sub-investigator: October 2008 Ongoing: Bristol-Meyers Squibb A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm study to Evaluate the Efficacy and Safety of study drug in preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation (The ARISTOTLE Trial) Cardiovascular Institute of the South, Houma, LA Sub-Investigator: October 2008 Ongoing: Novartis Pharmaceuticals Corp. A 8-week, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of approved study drug vs. approved study drug in Obese patients (BMI>=30) with Stage 2 Hypertension. (The ATTAIN Trial) Cardiovascular Institute of the South, Houma, LA Sub-Investigator: March 2007 Ongoing: Novartis Pharmaceuticals, Inc. A 36-week, multicenter, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of study medication on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy. (The ASPIRE Trial) Cardiovascular Institute of the South, Houma, LA Sub-Investigator: August 2008 November 2008: Cogentus Pharmaceuticals, Inc. A Randomized, double-blind, Double-Dummy, parallel group, Phase 3 Efficacy and safety Study of study drug compared with clopidogrel to reduce upper gastrointestinal events including bleeding and symptomatic ulcer disease." (The Cogent-1 Trial) Cardiovascular Institute of the South, Houma, LA CLINICAL TRIALS Sub Investigator: April 2010 Ongoing CVRx, Inc. IDE No: G Health Outcomes Prospective Evaluation for Heart Failure with EF > 40 % (HOPE4HF) Cardiovascular Institute of the South, Houma, LA Sub- Investigator: September 9, 2009 Ongoing IDev Technologies, Inc. IDE No: G Comparison of the SUPERA PERIPHEAL System to A Performance Goal Derived From Balloon Angioplasty Clinical Trials In The Superficial Femoral Artery (The SUPERB Study) Protocol No. SFA-1-US/EU Terrebonne General Medical Center, Houma, LA

5 QUSTIONNAIRE TRIALS / REGISTRIES Sub-Investigator: August 2008 Ongoing Terumo Medical Corporation. Clinical Experience with Terumo Pinnacle TIF tip Sheath Set System (The Terumo Trial) Cardiovascular Institute of the South, Houma, LA DEVICE TRIALS Sub-Investigator: 2008 Ongoing Abbott Vascular JoStent GraftMaster Coronary Stent Graft and Delivery System HUD (The JoStent Trial) Terebonne General Medical Center, Houma, LA